Track topics on Twitter Track topics that are important to you
Iceni BioDiscovery Ltd is a product-focused biotechnology company that is developing commercial cell therapies for unmet medical needs. Iceni will initially target diabetes where recent success in transplantation has created a requirement for more human tissue than is available from organ donors. Diabetes is a major and growing disease that would substantially benefit from a new treatment to restore physiological control of blood glucose levels. Nine percent of the UK National Health Service budget is spent on costs related to diabetes and its complications, islet transplantation is the only treatment for diabetes that can avoid these complications. Iceni’s products are based on insulin-producing cells, grown in the laboratory, that will greatly increase the number of patients that can receive a transplant. Products for treating other chronic diseases are in the pipeline. The Intellectual Property being developed by Iceni also opens opportunities for commercial collaborations and out-licensing.
Iceni obtained seed funding from Avlar and Prelude in April 2001 and completed a £3 million equity investment from three venture capital funds (Avlar, Novartis Venture Fund and Prelude) at the beginning of July 2001. A second round of funding will be completed in early 2003.
VAT on report purchase of $950
During BioTrinity 2014 Olivier Litzka, Partner, Edmond de Rothschild Investment Partners talks to Fintan Walton about BioDiscovery IV and how they will be investing the fund.
David Russell, left, chief scientific officer, and Rob Field, chief executive of Iceni Diagnostics at work in their lab. Picture: DENISE BRADLEY.
Oxford, UK, 1 November 2017: e-Therapeutics plc (AIM: ETX), a company pioneering the use of Network-Driven Drug Discovery (NDD) to create new and better drugs, announces the appointment of Christine...
CRANBURY, N.J., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today announced that it entered into a Purchase Agreement on September 7, 2017 with GMS Tenshi Holdings Pte. Li...
MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the developmen...
JERSEY, Channel Islands, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Execut...
Famotidine Tablets, USP 20 mg
Facility Maintenance Instant Hand Sanitizer HS-67
Amar ICE GEL
New rules for access and benefit sharing (ABS) of genetic resources and associated traditional knowledge have been established by the Nagoya Protocol but have not kept up with rapid scientific and tec...
Venoms can deleteriously affect any physiological system reachable by the bloodstream, including directly interfering with the coagulation cascade. Such coagulopathic toxins may be anticoagulants or p...
Theraphosid spiders (tarantulas) are venomous arthropods found in most tropical and subtropical regions of the world. Tarantula venoms are a complex cocktail of toxins with potential use as pharmacolo...
Polyextremophiles are present in a wide variety of extreme environments in which they must overcome various hostile conditions simultaneously such as high UVB radiation, extreme pHs and temperatures, ...
Iceni BioDiscovery Ltd is a product-focused biotechnology company that is developing commercial cell therapies for unmet medical needs. Iceni will initially target diabetes where recent success in tr...
Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...
BDNZ is New Zealandâ€™s leading centre of expertise on Bacillus thuringiensis (Bt) and high throughput screening (HTS) of invertebrate pests. Key activities include isolation and evaluation of B...
Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...
We have published hundreds of Iceni BioDiscovery Limited news stories on BioPortfolio along with dozens of Iceni BioDiscovery Limited Clinical Trials and PubMed Articles about Iceni BioDiscovery Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Iceni BioDiscovery Limited Companies in our database. You can also find out about relevant Iceni BioDiscovery Limited Drugs and Medications on this site too.
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...